Spots Global Cancer Trial Database for xeloda
Every month we try and update this database with for xeloda cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy | NCT00189683 | Colorectal Canc... | Monitoring Xeloda | 18 Years - | Association Européenne de Recherche en Oncologie | |
| Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine | NCT00478686 | Breast Cancer | Phlebotomy | - | M.D. Anderson Cancer Center | |
| Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer | NCT00614653 | Pancreatic Canc... | Bevacizumab Erlotinib Capecitabine Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Safety Of Xeloda as Sequential Adjuvant Therapy After Chemotherapy in Breast Cancer | NCT01662128 | Breast Cancer | Xeloda | - | Tianjin Medical University | |
| Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma | NCT02360501 | Nasopharyngeal ... | Docetaxel Cisplatin Capecitabine | 18 Years - 75 Years | Sun Yat-sen University | |
| A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer. | NCT00576901 | Breast Cancer | bevacizumab [Av... Docetaxel Xeloda | 18 Years - | Hoffmann-La Roche | |
| A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract. | NCT00448136 | Neoplasms | bevacizumab [Av... 5 FU Streptozotocin Xeloda | 18 Years - | Hoffmann-La Roche | |
| Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy | NCT00189683 | Colorectal Canc... | Monitoring Xeloda | 18 Years - | Association Européenne de Recherche en Oncologie | |
| Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer | NCT02068131 | Metastatic Colo... | Novaferon Capecitabine | 18 Years - | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | |
| Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma | NCT02786641 | Nasopharyngeal ... | Docetaxel Cisplatin 1 Xeloda IMRT Cisplatin 2 | 18 Years - 65 Years | Sun Yat-sen University | |
| Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine | NCT00478686 | Breast Cancer | Phlebotomy | - | M.D. Anderson Cancer Center | |
| Concurrent Xeloda and Radiotherapy for Bone Metastases | NCT00192777 | Solid Tumors Bone Metastases | Xeloda External Beam R... | 18 Years - | Rambam Health Care Campus | |
| CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater | NCT01202409 | Gastrointestina... | Panitumumab | 18 Years - | M.D. Anderson Cancer Center | |
| Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer | NCT00050167 | Breast Cancer | Paclitaxel Docetaxel Capecitabine | - | M.D. Anderson Cancer Center | |
| Capecitabine Pharmacokinetics(PK)-Actual Versus Ideal Body Weight | NCT01828554 | Obesity Neoplasms | Xeloda | 18 Years - | University of Wisconsin, Madison | |
| Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma | NCT02360501 | Nasopharyngeal ... | Docetaxel Cisplatin Capecitabine | 18 Years - 75 Years | Sun Yat-sen University | |
| PRECISE CURATE.AI Pilot Clinical Trial | NCT04522284 | Solid Tumor | CURATE.AI Capecitabine XELOX XELIRI Ibrutinib | 21 Years - 99 Years | National University Hospital, Singapore | |
| A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer | NCT02748213 | Breast Cancer | Xeloda Taxotere Herceptin | 18 Years - | Hoffmann-La Roche | |
| XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib | NCT00920868 | Solid Tumor Metastatic Colo... | dasatinib bevacizumab Oxaliplatin Capecitabine | 18 Years - | Duke University | |
| SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients | NCT03448549 | Colorectal Canc... Adjuvant Chemot... | Oxaliplatin Tegafur，gimerac... Xeloda | 18 Years - | Peking University Cancer Hospital & Institute | |
| A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer | NCT02025192 | HER2 Positive M... | Tucatinib Capecitabine Trastuzumab | 18 Years - | Seagen Inc. | |
| XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib | NCT00920868 | Solid Tumor Metastatic Colo... | dasatinib bevacizumab Oxaliplatin Capecitabine | 18 Years - | Duke University | |
| A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer | NCT00483834 | Colorectal Canc... | Bevacizumab Irinotecan Capecitabine | 18 Years - | University Health Network, Toronto | |
| A Bioequivalence Study of Capecitabine Tablets | NCT01846650 | Metastatic Brea... | Capecitabine ta... XELODA | 18 Years - 70 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. | NCT00577031 | Colorectal Canc... | bevacizumab [Av... Oxaliplatin Xeloda | 18 Years - | Hoffmann-La Roche | |
| Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer | NCT02581501 | Pancreatic Canc... | GAX - Gemcitabi... | 18 Years - | Stamford Hospital | |
| Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer | NCT02581501 | Pancreatic Canc... | GAX - Gemcitabi... | 18 Years - | Stamford Hospital | |
| Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | NCT06409390 | Metastatic Brea... | Taxotere Cytoxan Trastuzumab der... Sacituzumab gov... Xeloda Fulvestrant Ribociclib Abemaciclib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer | NCT00123851 | Colorectal Canc... Neoplasm Metast... | Tarceva (OSI-77... Capecitabine Oxaliplatin | 18 Years - | Dana-Farber Cancer Institute | |
| Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer | NCT00078572 | Breast Cancer | capecitabine lapatinib (GW57... | 18 Years - | GlaxoSmithKline | |
| Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism | NCT00960544 | Breast Cancer | Capecitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma | NCT02360501 | Nasopharyngeal ... | Docetaxel Cisplatin Capecitabine | 18 Years - 75 Years | Sun Yat-sen University | |
| Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab | NCT01213238 | Advanced Cancer... | Oxaliplatin Capecitabine Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer | NCT01300962 | Metastatic Brea... | BMK120 Capecitabine BYL719 Trastuzumab Lapatinib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer | NCT01200212 | Breast Cancer | Taxane, Avastin Taxane, Avastin... | 18 Years - | German Breast Group | |
| 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients | NCT00504660 | Anaplastic Glio... Glioblastoma Mu... Brain Cancer | Capecitabine Celecoxib (Cele... Temozolomide Lomustine 6-Thioguanine | 12 Years - | M.D. Anderson Cancer Center | |
| Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma | NCT02621970 | Nasopharyngeal ... | Cisplatin 1 Cisplatin 2 Docetaxel Xeloda Intensity-modul... | 18 Years - 60 Years | Sun Yat-sen University | |
| Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab | NCT01213238 | Advanced Cancer... | Oxaliplatin Capecitabine Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer | NCT02688712 | Rectal Adenocar... | LY2157299 Capecitabine Fluorouracil Tumor specific ... | 18 Years - | Providence Health & Services | |
| Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer | NCT00678535 | Gastric Cancer | Cetuximab Capecitabine Cisplatin | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer | NCT00905047 | Colorectal Canc... | XELODA TEGAFUR URACIL ... | 18 Years - | Centre Oscar Lambret | |
| Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer | NCT00678535 | Gastric Cancer | Cetuximab Capecitabine Cisplatin | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors | NCT00726687 | Advanced Solid ... | indibulin capecitabine | 18 Years - | Alaunos Therapeutics | |
| Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer | NCT00905047 | Colorectal Canc... | XELODA TEGAFUR URACIL ... | 18 Years - | Centre Oscar Lambret | |
| Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer | NCT02324543 | Metastatic Panc... | Gemcitabine Taxotere Xeloda Cisplatin Irinotecan | 18 Years - 76 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer | NCT00153907 | Breast Cancer | Navelbine Capecitabine | 18 Years - | Dana-Farber Cancer Institute | |
| Azacitidine and CAPOX in Metastatic Colorectal Cancer | NCT01193517 | Colorectal Canc... | Azacitidine Capecitabine Oxaliplatin Azacitidine MTD | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer | NCT01679327 | Colorectal Canc... | Oxaliplatin Xeloda Calcium folinat... 5-FU Bevacizumab | 18 Years - | ChineseAMS | |
| Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer | NCT00093379 | Anal Cancer | Capecitabine Oxaliplatin Radiation Thera... | 16 Years - | M.D. Anderson Cancer Center | |
| Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer | NCT02842125 | Metastatic Soli... Recurrent Head ... | Ad-P53 Xeloda Keytruda Opdivo | 18 Years - | MultiVir, Inc. | |
| Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients | NCT00338039 | Pancreatic Canc... | Cetuximab Gemcitabine Oxaliplatin Capecitabine Radiotherapy | 18 Years - | M.D. Anderson Cancer Center | |
| Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients | NCT00338039 | Pancreatic Canc... | Cetuximab Gemcitabine Oxaliplatin Capecitabine Radiotherapy | 18 Years - | M.D. Anderson Cancer Center | |
| A Bioequivalence Study of Capecitabine Tablets 500 mg in Adult Cancer Patients Under Fed Condition | NCT03435666 | Colon Cancer Breast Cancer | Capecitabine XELODA | 18 Years - 60 Years | Qilu Pharmaceutical Co., Ltd. | |
| A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer | NCT02748213 | Breast Cancer | Xeloda Taxotere Herceptin | 18 Years - | Hoffmann-La Roche | |
| Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer | NCT01498458 | Metastatic Brea... | Pazopanib plus ... | 18 Years - | German Breast Group | |
| Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer | NCT02060669 | Metastatic Colo... | Xeloda | 18 Years - | Samsung Medical Center | |
| Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer | NCT02842125 | Metastatic Soli... Recurrent Head ... | Ad-P53 Xeloda Keytruda Opdivo | 18 Years - | MultiVir, Inc. | |
| Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism | NCT00960544 | Breast Cancer | Capecitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer | NCT00153881 | Esophageal Neop... | Capecitabine (X... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Efficacy and Safety Of Xeloda as Sequential Adjuvant Therapy After Chemotherapy in Breast Cancer | NCT01662128 | Breast Cancer | Xeloda | - | Tianjin Medical University | |
| Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer | NCT05288777 | Breast Cancer Breast Cancer S... Breast Cancer S... Breast Cancer S... | T-DM1 Capecitabine External Beam R... External Beam R... | 18 Years - | University of Virginia | |
| Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer | NCT02581501 | Pancreatic Canc... | GAX - Gemcitabi... | 18 Years - | Stamford Hospital | |
| A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN) | NCT00196872 | Breast Cancer | Epirubicine Cyclophosphamid... Taxol Xeloda Ibandronat | 18 Years - 65 Years | German Breast Group | |
| Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer | NCT01941771 | Breast Cancer | Arm B Vinorelbi... Arm A Vinorelbi... | 18 Years - | University of Aarhus | |
| A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer | NCT02614794 | HER2 Positive B... | tucatinib capecitabine trastuzumab placebo | 18 Years - | Seagen Inc. | |
| SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients | NCT03448549 | Colorectal Canc... Adjuvant Chemot... | Oxaliplatin Tegafur，gimerac... Xeloda | 18 Years - | Peking University Cancer Hospital & Institute | |
| Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer | NCT00820222 | Metastases, Bra... | capecitabine lapatinib trastuzumab | 18 Years - | Novartis | |
| Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer | NCT00050167 | Breast Cancer | Paclitaxel Docetaxel Capecitabine | - | M.D. Anderson Cancer Center | |
| QYHJ Granules Versus Xeloda in Metastatic Pancreatic Cancer | NCT01796782 | Metastatic Panc... | Xeloda QYHJ Granules | 18 Years - | Fudan University | |
| Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | NCT06409390 | Metastatic Brea... | Taxotere Cytoxan Trastuzumab der... Sacituzumab gov... Xeloda Fulvestrant Ribociclib Abemaciclib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Capecitabine to Treat Recurrent High Grade Gliomas | NCT00717197 | Malignant Gliom... | Capecitabine | 18 Years - | University of Florida | |
| Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer | NCT02324543 | Metastatic Panc... | Gemcitabine Taxotere Xeloda Cisplatin Irinotecan | 18 Years - 76 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer | NCT00113230 | Rectal Cancer | Avastin (Bevaci... Capecitabine Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Brain Metastases In ErbB2-Positive Breast Cancer | NCT00437073 | Neoplasms, Brea... | capecitabine topotecan lapatinib | 18 Years - | GlaxoSmithKline | |
| Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer | NCT01470742 | Gastric Cancer | XELOX XELODA | 70 Years - | Samsung Medical Center | |
| A Bioequivalence Study of Capecitabine Tablets | NCT01846650 | Metastatic Brea... | Capecitabine ta... XELODA | 18 Years - 70 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer | NCT00050167 | Breast Cancer | Paclitaxel Docetaxel Capecitabine | - | M.D. Anderson Cancer Center | |
| A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer. | NCT00576901 | Breast Cancer | bevacizumab [Av... Docetaxel Xeloda | 18 Years - | Hoffmann-La Roche | |
| Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer | NCT01470742 | Gastric Cancer | XELOX XELODA | 70 Years - | Samsung Medical Center | |
| Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma | NCT00338988 | Cancer of the G... Cancer of the B... | Capecitabine Oxaliplatin | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
